Yicura BioMed Advances Dual Capital and Industrial Strategy： Completes First Closing of Series B Financing Led by Gobi Partners

ملخص مفصل

HONG KONG SAR – Media OutReach Newswire – 13 November 2026 – Yicura BioMed ("Yicura"), a clinical-stage immunotherapy company based in the Hong Kong Science Park developing…

The issuer is solely responsible for the content of this announcement.

Yicura BioMed ("Yicura") is a clinical-stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of immunotherapies for cancers, inflammations, and infectious diseases based on its patented PD-1-enhanced DNA vaccine and anti-Δ42PD1 antibody platforms.

Founded in 2002, Gobi Partners is a leading pan-Asian investment firm specialising in bespoke capital solutions for family offices, sovereign wealth funds, financial institutions and corporate investors. Headquartered in Hong Kong and Kuala Lumpur, Gobi manages US$2 billion across 30+ investment vehicles, investing in early to growth-stage companies with the potential for generational and global impact. The firm's team of over 90 investment professionals operates from 18 locations, curating a diversified portfolio of more than 400 companies, with 76 exits achieved to date.

مطلع المقال، مقتطف من Malay Mail. لقراءة المقال كاملًا، افتحه على موقع الناشر.